2024-06-20 3:43 PM

Migraine Treatment Has Come a Long Way

By Christina Jewett of The New York Times

If you don’t suffer from migraine headaches, you probably know at least one person who does. Nearly 40 million Americans get them — 28 million of them women and girls — making migraine the second most disabling condition in the world after low back pain. Several studies have found that migraine became more frequent during the pandemic, too.

I get migraine headaches, but thankfully they’re more bizarre than excruciating. Every few weeks, ocular migraine clouds my vision with strange zigzagging lights for a half-hour; and once or twice a year I get attacks that cause temporary memory loss. (One came on while I was grocery shopping, and I couldn’t remember what month or year it was, what I was there to buy or how old my kids were.)

Despite its ubiquity, research on migraine has long been underfunded. The National Institutes of Health spent only $40 million on migraine research in 2021; by comparison, it spent $218 million researching epilepsy, which afflicts one-twelfth as many Americans. Why is this devastating condition so woefully understudied?

“It’s a woman’s disease,” explained Dr. Robert Cowan, a neurologist and a former director of the Stanford Headache Program. In other words, he said, sexism almost certainly plays a role in medicine’s apathy toward the condition.

The good news is that over the past several years, the medical establishment has become more interested in the issue, and a handful of new treatments for migraine have been approved by the Food and Drug Administration. Some of them are quite promising. Here’s what migraine sufferers should know about today’s treatment landscape.

Recognize the symptoms of migraine and get a diagnosis.

Far too many Americans with migraine suffer in silence. “Fewer than 30 percent of people suffering with migraine seek medical advice, and only some of those patients will receive an appropriate migraine treatment,” said Dr. Santiago Mazuera, a neurologist at the Sandra and Malcolm Berman Brain & Spine Institute in Baltimore.

This ‘woman’s disease’ doesn’t get a lot of research funding, but the medical establishment has made strides in developing new drugs and devices to combat migraine over the last five years. (Delcan and Co./The New York Times) — FOR EDITORIAL USE ONLY WITH NYT STORY SCI MIGRAINE TREATMENT BY MELINDA WNNER MOYER FOR JULY 14, 2022. ALL OTHER USE PROHIBITED. —

Migraine is a neurological disorder and it differs from garden-variety headaches. People are likely to suffer from migraine if they have had at least five headache attacks in their lives, each lasting between four and 72 hours, and if the pain fulfills two out of these four criteria: It throbs or pulsates; it is on one side of the head; it is moderate to severe; it worsens with activity. Also, these attacks must cause either nausea or sensitivity to light and sound.

If you think you might have migraine, see your primary care practitioner, Mazuera suggested. “There is better understanding of migraine within the primary care community in recent years and more knowledge about the newer treatments,” he said. But if you’re not getting the help you need, you might want to see a headache specialist or neurologist, said Dr. Seniha Ozudogru, a neurologist at Penn Medicine. People with migraine are also at increased risk for other disorders, including heart disease, stroke, epilepsy, anxiety and depression.

Try lifestyle changes and first-line treatments to start.

If you have migraine, consider keeping a headache diary, or downloading a migraine app, to identify possible triggers. Women, for instance, often have migraine pain right before their period; it can be treated in a variety of ways, including with an estrogen patch, Cowan said. Other common migraine triggers include stress, too much or too little sleep, caffeine, alcohol, weather changes, certain foods, dehydration, light and particular smells, according to the American Migraine Foundation.

Often, triggers are partial and additive: You might not get a migraine attack after drinking one glass of red wine, but a glass of red wine and a bad night’s sleep might do it, Cowan said. A headache diary can also help you identify your triggers and figure out if you have chronic migraine, which is defined as having headaches on 15 or more days per month for more than three months, and when at least eight of those headaches have migraine-like features.

Based on your symptoms and their frequency, your doctor may recommend a preventive migraine treatment to stop the headaches from starting. These types of medicines include antidepressants like amitriptyline, blood pressure medications such as propranolol and epilepsy drugs including valproate, Cowan said.

The problem with these drugs is that often “they have nasty side effects,” Cowan said, so they aren’t always recommended but every time I exercised, I felt lightheaded and faint.

Your doctor might suggest taking medication at the onset of migraine to ease your symptoms, in addition to or instead of preventive treatments. For treatment of migraine after onset, doctors have long prescribed triptans — drugs such as sumatriptan that reduce inflammation and constrict blood vessels — and anti-inflammatory pain medications such as ibuprofen. But these methods don’t always work either, and triptans can cause side effects like nausea and dizziness.

If you can’t get relief, discuss new treatments with your doctor.

Over the past five years, a handful of new drugs and devices have been approved for prevention and acute treatment of migraine.

Many of these drugs block the activity of a pain-related protein called monoclonal antibodies that are periodically injected or administered intravenously. There are also pills, called gepants and ditans (with brand names like Nurtec ODT, Ubrelvy and Reyvow) that can be taken at the onset of migraine to block the activity of CGRP. Rimegepant (Nurtec ODT) has been approved by the FDA to both prevent and treat migraine, Ozudogru said, which is notable because most drugs do only one or the other.

These drugs don’t seem to have significant side effects, Cowan said — though they can cause mild nausea — yet they aren’t usually prescribed until after a person has tried several first-line treatments. That’s in large part because the new drugs are expensive, he said. Ozudogru said some doctors are also cautious about trying the latest treatments because they are so new, and nobody can say how safe they are over the long term. Among other things, CGRP helps the body heal from strokes, so drugs that inhibit CGRP activity might hinder recovery in someone who has a stroke, she said.

Another medication that has been approved to treat chronic migraine in particular is the cosmetic drug Botox. It is injected into areas around the head and neck and is thought to work by blocking chemicals that carry pain signals to the brain. “I like Botox a lot,” Cowan said. But, he added, “not everybody can tolerate being stabbed in the head 31 times, even with a tiny needle.” Usually, too, Botox treatment is repeated every 12 weeks.

Several medical devices have also been approved in recent years to manage migraine. “These have good data,” Cowan said, and they are ideal for people who can’t tolerate medicines or are pregnant. Gammacore, a hand-held device, targets the vagus nerve in the neck. Nerivio, a smartphone-controlled device worn on the arm, uses electrical signals to disrupt pain pathways. Cefaly stimulates the trigeminal nerve on the forehead, and Relivion stimulates the trigeminal and occipital nerves.

Although these newer devices and treatments are promising, many patients struggle to get them covered by health insurance, Mazuera said. And they can be pricey: The list price for some monoclonal antibodies is more than $650 per monthly injection, and the Cefaly device costs $379. However, the Coalition for Headache and Migraine Patients, or CHAMP, has guides available to help patients navigate treatment costs using pharmaceutical company savings cards and financial assistance plans; and the Patient Advocate Foundation has resources available for handling insurance denials and appeals, among other things.

Migraine is debilitating, and it can be quite difficult to treat. But patients shouldn’t lose hope, Ozudogru said. When she sees a new patient with migraine, she reassures them: “I’m not going to give up,” she says. “We’ll keep trying.” And today, there are more treatment options than ever to choose from.





On Key

Stories that may interest you